Description

Stevanato Group Is Not Just A Packaging Story — Here’s Why GLP-1 Matters!

Stevanato Group commenced fiscal 2026 with solid momentum, as reflected in its first quarter results that aligned closely with management’s expectations. The company reported a 10% revenue increase at constant currency, reaching EUR 273.6 million, with growth largely driven by its Biopharmaceutical and Diagnostic Solutions (BDS) segment. This segment posted a 13% rise in revenue, fueled primarily by strong demand for pre-fillable syringes, which grew over 20% year-over-year, alongside contributions from cartridges and vials. Revenue from high-value solutions, primarily biologics, accounted for 47% of total revenue and grew 17%, supported by the increasing market presence of GLP1 therapies, which represented around 21-22% of total company revenue. The company highlighted ongoing secular tailwinds in biologics including biosimilars, monoclonal antibodies, and novel therapies, with a market transition favoring ready-to-use formats and subcutaneous administration. Gross profit margin improved slightly by 30 basis points to 27.